Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Progerinin Phase I Study in Healthy Volunteers
NCT04512963Phase 1Completed
- Sponsor
- PRG Science & Technology
- Start
- Aug 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Progerinin in Hutchinson-Gilford progeria syndrome (HGPS) and Werner syndrome (WS) (2 arms), sponsored by PRG Science & Technology. Primary endpoints: Incidence of Dose Limiting Toxicities, Incidence of Treatment-Emergent Adverse Events and 11 more. Started Aug 2020; status: completed.
02
Drugs
Progerinin
03
Conditions
Hutchinson-Gilford progeria syndrome (HGPS)Werner syndrome (WS)
Beyond the preview
Go deeper on NCT04512963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04512963.